This website does readability filtering of other pages. All styles, scripts, forms and ads are stripped. If you want your website excluded or have other feedback, use this form.

Novartis licenses out unwanted GlaxoSmithKline cancer drugs to Chinese biotech | FierceBiotech

Skip to main content

Twitter LinkedIn Facebook Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe


Novartis licenses out unwanted GlaxoSmithKline cancer drugs to Chinese biotech

This is the second deal between Novartis and the Chinese biotech over the past year. (Wikimedia Commons / Andrew / Flickr)

Novartis has penned a pact with Shanghai-based biotech Laekna that will see it work on a pair of oral pan-Akt kinase inhibitors.

Specifically, the deal is for afuresertib (ASB183) and uprosertib (UPB795), two cancer drugs in phase 1 and 2 trials for a variety of cancers and originally developed by GlaxoSmithKline before the asset swap between the two Big Pharmas a few years back.

Both have been tested against ovarian and gastric cancers, multiple myeloma, melanoma and other indications.


Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

But not all have gone smoothly, as two years ago, Novartis and Dana-Farber killed off a phase 2 trial for uprosertib (a.k.a. GSK2141795) and another drug in cervical cancer in the U.S. due to “reasons related to drug supply.”

Novartis said in a statement that it will have an equity stake in Laekna, along with upfront and development milestone payments, and royalties on future sales. But it gave no details on just what this is worth.

Laekna says it has already “has mapped out” several clear registration paths for NDA approval, potentially as the first in class medicine.

The two are no strangers to each other, as last year they struck a deal that saw the biotech acquire global rights to develop a CYP17 inhibitor (CFG920), an oral androgen inhibitor, for prostate cancer.

"Novartis is a global leader in oncology drug innovation. This is the second licensing agreement between Laekna and Novartis, adding to the previous licensing of CFG920 less than a year ago," said Dr. Chris Lu, founder and CEO of Laekna.

"We have demonstrated to Novartis that Laekna is a valuable collaborator with our strong commitment, experienced team and financing support from the top investment partners." 

Read more on oncology biotech Regulation Novartis China Shanghai

Suggested Articles


Ex-Obama health official becomes Google's chief health officer

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

by Amirah Al Idrus Oct 18, 2019 4:40pm Biotech

Gilead, Spring Bank's hep B combo shows 'incremental benefit'

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

by Amirah Al Idrus Oct 18, 2019 10:51am MedTech

J&J, Ethicon to pay $117M to settle states' mesh marketing suits

J&J and Ethicon reached a deal with the attorneys general of 41 states and DC, agreeing to pay nearly $117 million.

by Conor Hale Oct 18, 2019 10:13am